vivi response to covid-19
Don't Wait, Collaborate!
The ViVI Scientific Think Tank has been following the emergence of the novel coronavirus since December 31, and we have been in constant communication with our colleagues around the world who share our concern. Just two weeks prior to the announcement of the Outbreak by WHO, we participated in the GloPID-R meeting in London, UK, brainstorming how the world could better prepare for a global pandemic. When we met again for the ISARIC annual meeting during the last week of February, a Public Health Emergency of International Concern was already well underway.
Our goal during the COVID-19 pandemic is to provide digital tools, modeling skills and scientific know-how to collaborate and support stakeholders in surveillance, clinical trials, and vaccine development.
The Vaccine Safety Initiative is committed to ensuring that data generated during the COVID-19 pandemic are interoperable, accurate and unbiased. We work on innovative modeling solutions that can be used as downstream applications to our point-of-care clinical data solutions. We ensure that clinical endpoints are recorded accurately and responsibly to be reported to regulatory and public health agencies without delay. To enhance collaboration and interoperability, we participate in expert panels creating COVID-19 data standards.
Because of our decades of experience in influenza and other respiratory viruses, we will not think in the short term. In addition to dealing with the current global crisis, society will need to adapt to a New Normal. In the long haul, affordable real-time surveillance solutions will be required to keep us safe. Once the current crisis has been managed, we will continue our work in monitoring seasonal viruses and those with epi/pandemic potential.
Our team of experts in infectious diseases, immunology, medical anthropology, risk communication, machine learning and data science, can help you to tailor therapeutic and preventive solutions to those most at risk. To this end, we are already working with a number of community-based clinics and large hospital systems in COVID-19 research in the United States and Europe as well as with partners in Low and Middle Income Countries.
If you are interested in working with and/or to get access to our mobile apps or chatbots or if you like to solicit subject matter expertise, please complete this form and begin the collaboration process. We are contributing know-how to many different aspects of the global response.
7/20/2020 04:59:30 am
Private pediatric office.
8/19/2020 07:47:00 pm
To Whom it may concern:My name is Marcela Gillman Director for International Sales and part of the Covid19 Task Force for Cladd Medical. Cladd medical, is an infectious desease Company, located in Miami Florida, with 30 years of experience in epidemics and now Covid19, the first Pandemic.As you are aware, the World Health Organization assigns funds to different countries to support with efforts to eradicate Covid19. In this case Kenya.One of our largest clients Mwale Medical and Technology City in Kenya a 5000 bed hospital,, is looking for our assistance in locating rapid PCR test for the testing of Covid19, specially at the borders where 35 Kilometers of truckers wait to be tested to go across. Kenya only accepts PCR test. We request and plea your assistance to be able to locate a manufacturer in the Netherlands/UK of swab rapid PCR test to be used in the hospitals and at borders. Please let me know your thoughts and recommendations, on products equipment and any options. As you know the USA is very advanced on PCR testing, but we are obligated by the World Health Organisation, to distribute funds accordingly, with Countries with similar technologies.
2/26/2022 06:54:42 am
Mit Novavax -Totvirus -Impfstoff gegen Covid brauchen wir keine Impfgegner und Virusleugner mehr !!
4/13/2022 03:21:23 am
Such a great information. This is really very helpful for bloggers
12/8/2022 11:25:21 am
Hope to learn more about your work and organization.
Leave a Reply.